GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shenzhen New Industries Biomedical Engineering Co 300832.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

60.10

-0.53%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About Shenzhen New Industries Biomedical Engineering Co

Its shares trade on Shenzhen under the ticker 300832.SZ. It has been listed since 12 May 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.58bn and net income of CN¥1.62bn. At that date it held total assets of CN¥9.94bn and shareholders' equity of CN¥9.14bn.

Shenzhen New Industries Biomedical Engineering Co., Ltd. principally engages in the research, development, production, and sale of automatic chemiluminescence immunoassay instruments and supporting reagents. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2020-05-12. The firm operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The firm sells its products both in domestic and international markets, including Asia, Europe, America and Africa.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
12 May 2020
Employees
2,818
Website
snibe.com ↗

Leadership

Pay as last reported

  • Mr. Wei RaoChairman of the Board, General Manager, since 1997CN¥4.5m
  • Ms. Chenliu DingChief Financial Officer, Deputy General ManagerCN¥2.8m
  • Ms. Lei ZhangDeputy General Manager, Secretary of the BoardCN¥2.8m
  • Ms. Tinghua LiDeputy General ManagerCN¥2.6m
  • Ms. Haiyan LiuDeputy General ManagerCN¥2.8m
  • Mr. Jinyun YuanDeputy General ManagerCN¥1.8m
  • Mr. Xu LiDirector
  • Ms. Jie RaoDirectorCN¥1.2m
  • Mr. Heming WengDirector
  • Ms. Qianhui WuIndependent DirectorCN¥120,000
  • Ms. Min ZhangIndependent DirectorCN¥40,000
  • Mr. Yi ZhiIndependent DirectorCN¥40,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
72
Environment
83
Social
75
Governance
58
Direct emissions (scope 1)
1,138.78 t
Energy emissions (scope 2)
14,213.66 t
Women in the workforce
36.43%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shenzhen New Industries Biomedical Engineering Co Ltd employs 2818 full-time employees in Health Care sector.
  • The company operates three segments: Instruments, Reagents, and Accessories for in-vitro diagnostics.
  • Products are applied in examination of Gonads, thyroid gland, glucose metabolism, and kidney function.

Weaknesses

  • The company's IPO was on 12 May 2020, a relatively recent listing date.
  • The firm's domestic and international markets include Asia, Europe, America, and Africa.
  • The company's headquarters is in Shenzhen, Guangdong, which may limit regional expansion.

Opportunities

  • The company's products are used in multiple medical examinations across Asia and Europe.
  • The Reagents segment supports the sale of analyzers in domestic and international markets.
  • The Instruments segment produces MAGLUMI and Biossays analyzer series for global demand.

Threats

  • The company faces competition in the Health Care sector from other firms.
  • The company's products are limited to specific medical examinations like kidney function.
  • The company's international markets include Africa, which may present regulatory challenges.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.